Dosing of patients has begun in a Phase 2/3 clinical trial evaluating ATH-1017, Athira Pharma‘s investigational candidate for the treatment of mild to moderate Alzheimer’s disease. “Embarking on this trial to evaluate our new approach to treating Alzheimer’s is the start of a collective experience that will involve not only individuals with Alzheimer’s but their caregivers and family members,” Leen Kawas, PhD, president and CEO of Athira, said in a press release. Called LIFT-AD, the…
You must be logged in to read/download the full post.
The post Dosing Starts in Phase 2/3 Trial of Athira’s ATH-1017 for Alzheimer’s appeared first on BioNewsFeeds.